Related Experiment Video

Updated: Nov 18, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

502

Association of Morbid Progression With Overall Survival Among Patients With Multiple Myeloma: Validation of the

Aaron S Rosenberg1, Thierry Facon2, Kejal Parikh3

  • 1Division of Hematology/Oncology, University of California Davis School of Medicine, UC Davis Comprehensive Cancer Center, Sacramento, CA.

Clinical Lymphoma, Myeloma & Leukemia
|February 10, 2021
PubMed
Abstract

Insights

Morbid progressive disease (PD) in multiple myeloma (MM) is common and significantly worsens survival outcomes. Identifying morbid PD early is crucial for managing this incurable cancer.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • Multiple myeloma (MM) is an incurable blood cancer characterized by irreversible end-organ damage.
  • Progressive disease (PD) in MM can be either morbid, associated with CRAB symptoms (hypercalcemia, renal insufficiency, anemia, bone lesions), or asymptomatic biochemical progression.

Purpose of the Study:

  • To determine the incidence of morbid progressive disease (PD) in multiple myeloma (MM).
  • To evaluate the impact of morbid PD on patient survival and progression-free survival (PFS).

Main Methods:

  • A post hoc analysis was conducted using data from two phase III clinical trials.
  • The study included transplant-ineligible patients newly diagnosed with MM.

Main Results:

  • Of 2082 patients, 59.7% experienced PD, with 43.7% having morbid PD at first progression.
  • Patients with morbid PD had significantly worse second progression-free survival (PFS) and overall survival (OS) compared to those with asymptomatic PD.
  • Common morbid PD indicators included renal insufficiency (49.9%) and anemia (68.1%).

Conclusions:

  • Morbid progressive disease (PD) is a frequent event in multiple myeloma (MM) and is linked to poorer survival.
  • The occurrence of morbid PD, often associated with irreversible CRAB symptoms, highlights its significance as a clinical event.
  • The association of morbid PD with shortened PFS supports its validity as a relevant endpoint in MM clinical trials.
Keywords:
AnemiaHypercalcemiaMultiple MyelomaProgressionRenal insufficiency

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.8K
Predictive Immune Modeling of Solid Tumors08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.3K

Related Concept Videos

Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
393
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.9K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
523
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
403
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
Actuarial Approach01:20

Actuarial Approach

The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
190